title: Acetate- and Citrate-Specific Ion Effects on Unfolding and Temperature-Dependent Aggregation Rates of Anti-Streptavidin IgG1.
abstract: Controlling and predicting unwanted degradation, such as non-native aggregation, is a long-standing challenge for mAbs and other protein-based products. mAb aggregation rates are typically sensitive to temperature, pH, and the addition of excipients. Quantitatively comparing temperature-dependent aggregation rates across multiple possible formulations is a challenge in product development. A parallel temperature initial rate method is used to efficiently and accurately determine initial rates for anti-streptavidin (AS) IgG1 aggregation as a function of pH, [NaCl], and in the presence of acetate versus citrate buffer. Parallel temperature initial rates are shown to agree with results from a traditional, isothermal method and permits direct comparison of the formulations across almost 3 orders of magnitude of aggregation rates. The apparent midpoint unfolding temperatures (through differential scanning calorimetry) and the effective activation energy values (Ea) are generally higher in acetate buffer compared with citrate buffer, which is consistent with preferential accumulation of citrate ions compared with acetate ions that was speculated in previous work (Barnett et al., J Phys Chem B, 2015). Static light scattering and Kirkwood-Buff analysis show that AS-IgG1 has stronger net repulsive protein-protein interactions in acetate compared with citrate buffer, also consistent with increased values of Ea. In an extreme case, aggregation of AS-IgG1 is effectively eliminated across all practical temperatures at pH 4 in 10 mM sodium acetate but proceeds readily in citrate buffer.
authors.affiliation: Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19716.
authors.forename: Gregory V
authors.initials: GV
authors.lastname: Barnett
authors.affiliation: Drug Product Development, Amgen Inc., Seattle, Washington 98119.
authors.forename: Vladimir I
authors.initials: VI
authors.lastname: Razinkov
authors.affiliation: Drug Product Development, Amgen Inc., Seattle, Washington 98119.
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Kerwin
authors.affiliation: Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19716.
authors.forename: Alexander
authors.initials: A
authors.lastname: Hillsley
authors.affiliation: Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19716. Electronic address: cjr@udel.edu.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Roberts
mesh_terms: D000085:Acetates / Q000737:chemistry*; D000911:Antibodies, Monoclonal / Q000737:chemistry*; D002021:Buffers; D002626:Chemistry, Pharmaceutical / Q000379:methods; D019343:Citric Acid / Q000737:chemistry*; D005079:Excipients / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D007074:Immunoglobulin G / Q000737:chemistry*; D007477:Ions / Q000737:chemistry*; D066329:Protein Aggregates; D058767:Protein Unfolding; D019809:Streptavidin / Q000276:immunology*; D013696:Temperature
chemical_list: D000085:Acetates; D000911:Antibodies, Monoclonal; D002021:Buffers; D005079:Excipients; D007074:Immunoglobulin G; D007477:Ions; D066329:Protein Aggregates; D019343:Citric Acid; D019809:Streptavidin
keywords: calorimetry (DSC); formulation; high-performance liquid chromatography; protein aggregation; stability